ArticleCornea2017
Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
Article in Cornea, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- New Paradigm in Ocular Surface Squamous Neoplasia-Insights from a Case Report on the Use of Interferon in Treatment.Oncology research · 2026Article
- Topical 5-fluorouracil 1% versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia: a comparison of recurrences and side effects.BMC ophthalmology · 2025Article
- Efficacy, safety and cost-effectiveness of 5-fluorouracil versus interferon α-2b as adjuvant therapy after surgery in ocular surface squamous neoplasia in a southern European tertiary hospital.International ophthalmology · 2024Review
- Multidimensional immunotherapy for dry eye disease: current status and future directions.Frontiers in ophthalmology · 2024Review
- Case report: Clinical features and management outcomes of isolated corneal intraepithelial neoplasia.Frontiers in ophthalmology · 2024Article
- The Management of Ocular Surface Squamous Neoplasia (OSSN).International journal of molecular sciences · 2022Review
- Update on the Management of Ocular Surface Squamous Neoplasia.Current ophthalmology reports · 2021Article
- Ocular surface squamous neoplasia resistant to topical interferon alpha 2b in a patient with follicular lymphoma.International journal of ophthalmology · 2021Article
- Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.American journal of ophthalmology · 2019Article
- Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.International ophthalmology · 2019Observational
- Update on pharmacotherapy for ocular surface squamous neoplasia.Eye and vision (London, England) · 2019Review
- Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence.Ophthalmology and therapy · 2018Review
- Ocular surface squamous neoplasia in HIV-infected patients: current perspectives.HIV/AIDS (Auckland, N.Z.) · 2018Review
- Recombinant Interferon Alpha-2b as Primary Treatment for Ocular Surface Squamous Neoplasia.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe mechanism by which ocular surface squamous neoplasia (OSSN) responds to topical interferon-alpha-2b (IFNα2b) is not known. We report the cases of 3 immunosuppressed patients whose tumors did not respond to topical IFNα2b therapy. The purpose of this series is to shed light on potential mechanisms of IFNα2b in OSSN.
methodsRetrospective case series of 3 immunosuppressed patients whose biopsy-proven OSSN did not respond to topical IFNα2b treatment.
resultsThree white, immunosuppressed males (mean age 70 years, range 66-76) were diagnosed with OSSN. Topical IFNα2b 1 million units/mL was administered 4 times a day and used for a mean of 5 months (range 2-7 mo) without an adequate response. All patients were then switched to 5-fluorouracil. Successful eradication of OSSN was achieved in 2 cases, and improvement of OSSN in another. The latter patient was switched to mitomycin-C with subsequent resolution of OSSN.
conclusionsThese cases suggest that an intact immune system may be an important link between IFNα2b therapy and tumor resolution. As such, topical IFNα2b may not be an optimal choice for patients with underlying immunosuppression. It may be more effective in this patient population to switch to a non-immune-modulating therapy such as 5-fluorouracil or mitomycin-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.